C2i Genomics, an Israeli medtech startup that develops new procedures for the treatment of cancer, is being acquired by American cancer diagnostics company Veracyte for as much as $95 million. Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones […]
Grew full-year revenue to between $358 million and $359 million, an increase of 21%
Acquisition broadens Veracyte’s presence across the cancer care continuum
.
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.